Last 7 days
-29.5%
Last 30 days
-25.3%
Last 90 days
-9.0%
Trailing 12 Months
35.6%
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
BGNE | 311.1B | 1.6B | -10.47% | 70.40% | -162.26 | 199.76 | 77.54% | 1.62% |
ABBV | 285.4B | 56.7B | -9.71% | -7.25% | 24.12 | 4.92 | 0.03% | -39.22% |
REGN | 87.6B | 12.4B | -9.13% | 5.17% | 20.2 | 7.2 | -25.07% | -47.28% |
VRTX | 83.8B | 9.2B | -4.53% | 18.84% | 25.7 | 9.1 | 15.86% | 32.99% |
ALNY | 23.2B | 1.0B | -6.40% | 45.93% | -21.75 | 22.33 | 22.88% | -19.27% |
SRPT | 11.6B | 975.7M | 1.67% | 67.21% | -10.42 | 11.92 | 27.41% | -212.78% |
UTHR | 9.6B | 2.0B | -10.84% | -12.99% | 13.17 | 4.84 | 12.05% | 52.86% |
MID-CAP | ||||||||
MDGL | 5.1B | - | -10.25% | 307.66% | -16.27 | 2.5K | - | -27.52% |
BPMC | 3.4B | 204.6M | 10.50% | 0.21% | -5.87 | 16.66 | -7.52% | 10.65% |
RARE | 3.4B | 363.3M | 10.85% | -0.47% | -4.8 | 9.35 | 3.39% | -55.81% |
MRTX | 2.2B | 18.9M | -16.27% | -6.81% | -2.93 | 114.18 | - | -16.17% |
SMALL-CAP | ||||||||
CYTK | 3.6B | - | 1.50% | -9.34% | -8.36 | 38.06 | 34.30% | -67.22% |
CPRX | 1.2B | 256.5M | -27.45% | 57.57% | 12.31 | 4.77 | 66.85% | 120.61% |
MGNX | 288.8M | 165.3M | -32.22% | 33.43% | -3.16 | 1.75 | 130.70% | 57.97% |
CRBP | 37.4M | - | 1.03% | 2894.60% | -0.74 | 19.11 | - | -29.84% |
Income Statement (Last 12 Months) | ||||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
Revenue | 10.3% | 770,447,000 | 698,801,000 | 696,617,000 | 618,233,000 | 569,383,000 |
Operating Expenses | 9.0% | 1,248,952,000 | 1,146,210,000 | 1,028,418,000 | 974,923,000 | 932,204,000 |
S&GA Expenses | 4.2% | 339,642,000 | 325,998,000 | 319,829,000 | 308,963,000 | 297,949,000 |
R&D Expenses | 8.4% | 706,543,000 | 651,496,000 | 612,647,000 | 578,030,000 | 546,249,000 |
EBITDA | -6.1% | -440,188,000 | -414,942,000 | -439,120,000 | -424,644,000 | - |
EBITDA Margin | -5.8% | -0.63 | -0.60 | -0.71 | -0.75 | - |
Earnings Before Taxes | -2.2% | -600,586,000 | -587,487,000 | -536,402,000 | -542,854,000 | -512,041,000 |
EBT Margin | -9.2% | -0.84 | -0.77 | -0.88 | -0.90 | - |
Interest Expenses | 37.0% | 25,289,000 | 18,463,000 | 12,678,000 | 12,679,000 | 10,536,000 |
Net Income | -2.2% | -571,250,000 | -559,017,000 | -531,393,000 | -555,702,000 | -521,985,000 |
Net Income Margin | -4.9% | -0.80 | -0.76 | -0.90 | -0.92 | - |
Free Cahsflow | -33.3% | -388,670,000 | -291,651,000 | -305,258,000 | -280,435,000 | - |
Balance Sheet | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
Assets | -5.7% | 1,609 | 1,706 | 1,576 | 1,804 | 1,800 |
Current Assets | -11.6% | 613 | 694 | 517 | 695 | 774 |
Cash Equivalents | -40.1% | 167 | 280 | 104 | 158 | 152 |
Inventory | 22.2% | 27.00 | 22.00 | 15.00 | 15.00 | 15.00 |
Net PPE | 9.5% | 79.00 | 73.00 | 67.00 | 65.00 | 59.00 |
Goodwill | 0.0% | 82.00 | 82.00 | 82.00 | 82.00 | 82.00 |
Liabilities | 0.7% | 2,066 | 2,053 | 1,803 | 1,986 | 1,890 |
Current Liabilities | 8.7% | 442 | 406 | 420 | 567 | 477 |
LT Debt, Current | 0.1% | 150 | 150 | - | - | - |
LT Debt, Non Current | 0.1% | 572 | 572 | 283 | 282 | 282 |
Shareholder's Equity | -31.8% | -457 | -347 | -90.58 | - | - |
Retained Earnings | -5.2% | -2,795 | -2,656 | -2,486 | -2,376 | -2,224 |
Additional Paid-In Capital | 1.5% | 2,340 | 2,305 | 2,223 | 2,184 | 2,153 |
Shares Outstanding | 1.2% | 74.00 | 73.00 | 72.00 | 72.00 | 71.00 |
Cashflow (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
Cashflow From Operations | 19.0% | -288 | -356 | -259 | -272 | -248 |
Share Based Compensation | 2.0% | 113 | 110 | 109 | 106 | 104 |
Cashflow From Investing | -26.9% | 212 | 290 | 326 | 254 | 238 |
Cashflow From Financing | 1.7% | 171 | 168 | -130 | 12.00 | 13.00 |
97.7%
75.8%
17.7%
Y-axis is the maximum loss one would have experienced if PTC Therapeutics was unfortunately bought at previous high price.
26.0%
4.0%
-6.7%
FIve years rolling returns for PTC Therapeutics.
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-05-26 | ProShare Advisors LLC | reduced | -10.67 | 76,430 | 648,369 | -% |
2023-05-23 | Brookfield Corp /ON/ | reduced | -4.95 | 864,244 | 5,053,740 | 0.02% |
2023-05-22 | AMERIPRISE FINANCIAL INC | added | 56.04 | 1,943,300 | 3,926,300 | -% |
2023-05-22 | PUTNAM INVESTMENTS LLC | reduced | -20.17 | 30,212 | 2,334,420 | -% |
2023-05-18 | INTERNATIONAL BIOTECHNOLOGY TRUST PLC | reduced | -35.42 | -988,680 | 4,504,920 | 1.26% |
2023-05-18 | JPMORGAN CHASE & CO | added | 0.78 | 9,174,000 | 42,068,000 | -% |
2023-05-18 | NEW YORK STATE COMMON RETIREMENT FUND | reduced | -7.55 | 506,000 | 3,424,000 | -% |
2023-05-17 | VIRGINIA RETIREMENT SYSTEMS ET AL | reduced | -11.67 | -197,798 | 404,602 | -% |
2023-05-16 | JANE STREET GROUP, LLC | new | - | 1,071,660 | 1,071,660 | -% |
2023-05-16 | SUSQUEHANNA FUNDAMENTAL INVESTMENTS, LLC | reduced | -24.29 | -180,951 | 4,430,710 | 0.10% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Feb 14, 2023 | rtw investments, lp | 7.7% | 5,615,387 | SC 13G/A | |
Feb 09, 2023 | janus henderson group plc | 2.8% | 2,027,142 | SC 13G/A | |
Feb 09, 2023 | fmr llc | - | 0 | SC 13G/A | |
Feb 09, 2023 | vanguard group inc | 10.21% | 7,339,520 | SC 13G/A | |
Feb 06, 2023 | wellington management group llp | 10.34% | 7,430,907 | SC 13G/A | |
Feb 01, 2023 | franklin resources inc | 4.8% | 3,489,687 | SC 13G/A | |
Jan 24, 2023 | blackrock inc. | 9.2% | 6,640,854 | SC 13G/A | |
Jul 11, 2022 | vanguard group inc | 10.07% | 7,183,692 | SC 13G/A | |
Feb 14, 2022 | rtw investments, lp | 7.5% | 5,293,966 | SC 13G/A | |
Feb 11, 2022 | hartford mutual funds inc/ct | 0% | 0 | SC 13G |
Date Filed | Form Type | Document | |
---|---|---|---|
May 24, 2023 | 4 | Insider Trading | |
May 23, 2023 | 144 | Notice of Insider Sale Intent | |
May 23, 2023 | 4 | Insider Trading | |
May 23, 2023 | 8-K | Current Report | |
May 22, 2023 | 144 | Notice of Insider Sale Intent | |
May 22, 2023 | 144 | Notice of Insider Sale Intent | |
May 19, 2023 | 144 | Notice of Insider Sale Intent | |
May 19, 2023 | 4 | Insider Trading | |
May 18, 2023 | 144 | Notice of Insider Sale Intent | |
May 17, 2023 | 144 | Notice of Insider Sale Intent |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-05-23 | Reeve Emma | acquired | 88,520 | 33.3786 | 2,652 | - |
2023-05-23 | Reeve Emma | sold | -157,885 | 59.5342 | -2,652 | - |
2023-05-22 | Pauwels Eric | sold | -118,791 | 59.0122 | -2,013 | chief business officer |
2023-05-22 | Reeve Emma | acquired | 237,484 | 33.3733 | 7,116 | - |
2023-05-22 | Reeve Emma | sold | -423,630 | 59.5321 | -7,116 | - |
2023-05-19 | Pauwels Eric | sold | -377,491 | 58.9553 | -6,403 | chief business officer |
2023-05-18 | Pauwels Eric | sold | -46,266 | 58.7143 | -788 | chief business officer |
2023-05-17 | Pauwels Eric | sold | -470,822 | 58.5017 | -8,048 | chief business officer |
2023-05-11 | Jacobson Allan Steven | sold | -1,266,930 | 55.0839 | -23,000 | - |
2023-05-11 | Jacobson Allan Steven | acquired | 249,550 | 10.85 | 23,000 | - |
Consolidated Statements of Operations - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2023 | Mar. 31, 2022 | |
Revenues: | ||
Revenue | $ 220,382 | $ 148,735 |
Operating expenses: | ||
Cost of product sales, excluding amortization of acquired intangible assets | 14,144 | 10,135 |
Amortization of intangible assets | 39,415 | 23,473 |
Research and development | 195,124 | 140,078 |
Selling, general and administrative | 86,914 | 73,271 |
Change in the fair value of deferred and contingent consideration | 2,400 | (11,700) |
Total operating expenses | 337,997 | 235,257 |
Loss from operations | (117,615) | (86,522) |
Interest expense, net | (27,331) | (23,514) |
Other income (expense), net | 9,956 | (11,855) |
Loss before income tax expense | (134,990) | (121,891) |
Income tax expense | (3,969) | (4,835) |
Net loss attributable to common stockholders | $ (138,959) | $ (126,726) |
Weighted-average shares outstanding: | ||
Basic | 73,729,284 | 71,215,105 |
Diluted | 73,729,284 | 71,215,105 |
Net loss per share-basic and diluted (in dollars per share) | ||
Basic | $ (1.88) | $ (1.78) |
Diluted | $ (1.88) | $ (1.78) |
Net product revenue | ||
Revenues: | ||
Revenue | $ 187,557 | $ 129,832 |
Collaboration revenue | ||
Revenues: | ||
Revenue | 6 | 7 |
Royalty revenue | ||
Revenues: | ||
Revenue | 30,831 | 18,896 |
Manufacturing revenue | ||
Revenues: | ||
Revenue | $ 1,988 | $ 0 |
Consolidated Balance Sheets - USD ($) $ in Thousands | Mar. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 167,495 | $ 279,834 |
Marketable securities | 118,808 | 130,871 |
Trade and royalty receivables, net | 201,867 | 155,614 |
Inventory, net | 26,649 | 21,808 |
Prepaid expenses and other current assets | 98,573 | 105,658 |
Total current assets | 613,392 | 693,785 |
Fixed assets, net | 79,492 | 72,590 |
Intangible assets, net | 686,205 | 705,891 |
Goodwill | 82,341 | 82,341 |
Operating lease ROU assets | 99,531 | 102,430 |
Deposits and other assets | 47,878 | 48,582 |
Total assets | 1,608,839 | 1,705,619 |
Current liabilities: | ||
Accounts payable and accrued expenses | 332,091 | 320,366 |
Deferred revenue | 214 | 1,351 |
Operating lease liabilities- current | 9,598 | 9,370 |
Finance lease liabilities- current | 1,857 | 3,000 |
Liability for sale of future royalties - current | 97,874 | 72,149 |
Total current liabilities | 441,634 | 406,236 |
Long-term debt | 572,091 | 571,722 |
Contingent consideration payable | 166,400 | 164,000 |
Deferred tax liability | 102,831 | 102,834 |
Operating lease liabilities- noncurrent | 100,442 | 100,860 |
Finance lease liabilities- noncurrent | 17,184 | 18,675 |
Liability for sale of future royalties- noncurrent | 665,677 | 685,737 |
Other long-term liabilities | 141 | 2,641 |
Total liabilities | 2,066,400 | 2,052,705 |
Stockholders' deficit: | ||
Common stock, $0.001 par value. Authorized 250,000,000 shares; issued and outstanding 74,012,034 shares at March 31, 2023. Authorized 250,000,000 shares; issued and outstanding 73,104,692 shares at December 31, 2022 | 73 | 72 |
Additional paid-in capital | 2,339,886 | 2,305,020 |
Accumulated other comprehensive (loss) income | (1,587) | 4,796 |
Accumulated deficit | (2,795,933) | (2,656,974) |
Total stockholders' deficit | (457,561) | (347,086) |
Total liabilities and stockholders' deficit | $ 1,608,839 | $ 1,705,619 |